Katerina Chatzidionysiou

Publikationer
Forskningsbidrag
CV
Populärvetenskap och samverkan

Artiklar

Article: ARTHRITIS & RHEUMATOLOGY. 2024
Effectiveness of JAK Inhibitors Compared With Biologic Disease-Modifying Antirheumatic Drugs on Pain Reduction in Rheumatoid Arthritis: Results From a Nationwide Swedish Cohort Study
Eberhard A; Di Giuseppe D; Askling J; Bergman S; Bower H; Chatzidionysiou K; Forsblad-d'Elia H; Kastbom A; Olofsson T; Frisell T; Turesson C
Article: EUROPEAN JOURNAL OF CANCER. 2024;207:114172
Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma.
Verheijden RJ; Burgers FH; Janssen JC; Putker AE; Veenstra SPGR; Hospers GAP; Aarts MJB; Hehenkamp KW; Doornebosch VLE; Verhaert M; van den Berkmortel FWPJ; Chatzidionysiou K; Llobell A; Barros M; Maria ATJ; Takeji A; García Morillo J-S; Lidar M; van Eijs MJM; Blank CU; Aspeslagh S; Piersma D; Kapiteijn E; Labots M; Boers-Sonderen MJ; van der Veldt AAM; Haanen JBAG; May AM; Suijkerbuijk KPM
Article: IMMUNO-ONCOLOGY AND TECHNOLOGY. 2024;22:100713
Effect of glucocorticoids for the management of immune-related adverse events on outcome in melanoma patients treated with immunotherapy-a retrospective and biomarker study.
Costa Svedman F; Liapi M; Månsson-Broberg A; Chatzidionysiou K; Egyhazi Brage S
Article: LUPUS. 2024;33(6):615-628
Factors associated with non-adherence to medications in systemic lupus erythematosus: Results from a Swedish survey
Emamikia S; Gomez A; Adahl T; von Perner G; Enman Y; Chatzidionysiou K; Arkema EV; Parodis I
Article: MICROBIOLOGY SPECTRUM. 2024;12(4):e0298123-e02923
The serological immunogenicity of the third and fourth doses of COVID-19 vaccine in patients with inflammatory rheumatic diseases on different biologic or targeted DMARDs: a Swedish nationwide study (COVID-19-REUMA)
Frodlund M; Nived P; Chatzidionysiou K; Soedergren A; Klingberg E; Hansson M; Ohlsson S; Pin E; Bengtsson A; Klareskog L; Kapetanovic M
Article: RHEUMATOLOGY ADVANCES IN PRACTICE. 2024;8(2):rkae063
Determinants of tofacitinib discontinuation in adult patients with rheumatoid arthritis during long-term extension studies up to 9.5 years
Curtis JR; Wollenhaupt J; Tas SW; Chatzidionysiou K; Wang L; Roberts K; Tsekouras V
Article: RMD OPEN. 2023;9(4):e003648
Are JAKis more effective among elderly patients with RA, smokers and those with higher cardiovascular risk? A comparative effectiveness study of b/tsDMARDs in Sweden
Bower H; Frisell T; di Giuseppe D; Delcoigne B; Lindstrom U; Turesson C; Chatzidionysiou K; Lindqvist E; Knight A; Forsblad-d'Elia H; Askling J
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2023;52(6):591-600
Evaluation of an individually tailored smoking-cessation intervention for patients with rheumatoid arthritis in an outpatient clinic
Karlsson M-L; Hertzberg-Nyquist K; Saevarsdottir S; Lundberg IE; Demmelmaier I; Pettersson S; Chatzidionysiou K
Article: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2023;41(10):1985-1990
Original research on Behçet's syndrome: a bibliometric analysis over 20 years (2000-2019)
Bolla E; Chatzidionysiou K; Tektonidou MG; Sfikakis PP
Article: JOURNAL OF CLINICAL MEDICINE. 2023;12(16):5377
Intracardiac Thrombi in Morbus Adamantiades-Behcet in Two Swedish Patients
Da Mutten R; Borg A; Chatzidionysiou K; Parodis I
Article: VACCINE. 2023;41(20):3247-3257
The impact of immunomodulating treatment on the immunogenicity of COVID-19 vaccines in patients with immune-mediated inflammatory rheumatic diseases compared to healthy controls. A Swedish nationwide study (COVID19-REUMA)
Frodlund M; Nived P; Chatzidionysiou A; Sodergren A; Klingberg E; Bengtsson A; Hansson M; Olsson S; Pin E; Klareskog L; Kapetanovic MC
Article: PLOS ONE. 2023;18(12):e0295838
Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial
Sunden-Cullberg J; Chen P; Habel H; Skorup P; Janols H; Rasmuson J; Niward K; Balkhed AO; Chatzidionysiou K; Asgeirsson H; Blennow O; Parke A; Svensson A-K; Muvva JR; Ljunggren H-G; Horne A-C; Aden U; Henter J-I; Sonnerborg A; Vesterbacka J; Nowak P; Lampa J
Article: RHEUMATOLOGY. 2022;61(10):3952-3962
Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data
Barbulescu A; Askling J; Chatzidionysiou K; Forsblad-d'Elia H; Kastbom A; Lindstrom U; Turesson C; Frisell T
Article: SEMINARS IN ARTHRITIS AND RHEUMATISM. 2022;56:152050
Development and external validation of prediction models for adverse health outcomes in rheumatoid arthritis: A multinational real-world cohort analysis.
Yang C; Williams RD; Swerdel JN; Almeida JR; Brouwer ES; Burn E; Carmona L; Chatzidionysiou K; Duarte-Salles T; Fakhouri W; Hottgenroth A; Jani M; Kolde R; Kors JA; Kullamaa L; Lane J; Marinier K; Michel A; Stewart HM; Prats-Uribe A; Reisberg S; Sena AG; Torre CO; Verhamme K; Vizcaya D; Weaver J; Ryan P; Prieto-Alhambra D; Rijnbeek PR
Article: RMD OPEN. 2022;8(2):e002465
Risk of lung cancer in rheumatoid arthritis and in relation to autoantibody positivity and smoking
Chatzidionysiou K; di Giuseppe D; Soderling J; Catrina A; Askling J
Article: RHEUMATOLOGY. 2022;61(9):3647-3656
The occurrence of multiple treatment switches in axial spondyloarthritis. Results from five Nordic rheumatology registries
Di Giuseppe D; Lindstrom U; Aaltonen K; Relas H; Provan S; Gudbjornsson B; Hetland ML; Askling J; Kauppi M; Geirsson AJ; Chatzidionysiou K; Jorgensen TS; Dreyer L; Michelsen B; Jacobsson L; Glintborg B
Article: RHEUMATOLOGY. 2022;61(9):3596-3605
Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden
Di Giuseppe D; Lindstrom U; Bower H; Delcoigne B; Frisell T; Chatzidionysiou K; Sjowall C; Lindqvist E; Askling J
Article: CRITICAL REVIEWS IN IMMUNOLOGY. 2022;42(4):21-36
Using Autoantibodies to Diagnose Systemic Autoimmune Diseases Triggered by Immune Checkpoint Inhibitors: A Clinical Perspective.
Flores-Chávez A; Brito-Zerón P; Retamozo S; Bitoun S; Fisher BA; Liew D; Suijkerbuijk K; Chatzidionysiou K; Suárez-Almazor M; Lambotte O; Mariette X; Ramos-Casals M
Article: RMD OPEN. 2021;7(3):e001987
Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision
Bower H; Frisell T; di Giuseppe D; Delcoigne B; Ahlenius G-M; Baecklund E; Chatzidionysiou K; Feltelius N; Forsblad-d'Elia H; Kastbom A; Klareskog L; Lindqvist E; Lindstrom U; Turesson C; Sjowall C; Askling J
Article: JOURNAL OF RHEUMATOLOGY. 2021;48(10):1512-1518
Effectiveness of a Second Biologic After Failure of a Non-tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid Arthritis
Chatzidionysiou K; Hetland ML; Frisell T; Di Giuseppe D; Hellgren K; Glintborg B; Nordstrom D; Peltomaa R; Aaltonen K; Trokovic N; Kristianslund EK; Kvien TK; Provan SA; Gudbjornsson B; Grondal G; Dreyer L; Kristensen LE; Jorgensen TS; Jacobsson LTH; Askling J
Article: ANNALS OF THE RHEUMATIC DISEASES. 2021;80(8):1086-1093
Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study
Bower H; Frisell T; Di Giuseppe D; Delcoigne B; Ahlenius G-M; Baecklund E; Chatzidionysiou K; Feltelius N; Forsblad-d'Elia H; Kastbom A; Klareskog L; Lindqvist E; Lindstrom U; Turesson C; Sjowall C; Askling J
Article: RMD OPEN. 2021;7(2):e001662
Tocilizumab decreases T cells but not macrophages in the synovium of patients with rheumatoid arthritis while it increases the levels of serum interleukin-6 and RANKL
Chatzidionysiou K; Circiumaru A; Rethi B; Joshua V; Engstrom M; Hensvold A; af Klint E; Catrina A
Article: RHEUMATOLOGY. 2021;60(2):820-828
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries
Courvoisier DS; Chatzidionysiou K; Mongin D; Lauper K; Mariette X; Morel J; Gottenberg J-E; Bergstra SA; Suarez MP; Codreanu C; Kvien TK; Santos MJ; Pavelka K; Hetland ML; Askling J; Turesson C; Kubo S; Tanaka Y; Iannone F; Choquette D; Nordstrom DC; Rotar Z; Lukina G; Gabay C; Van Vollenhoven R; Finckh A
Article: MEDITERRANEAN JOURNAL OF RHEUMATOLOGY. 2020;31(Suppl 2):247-252
The Rheumatologist's Role in the Battle Against COVID-19: Insights from the Front Line and Challenges for the Future.
Koutsianas C; Chatzidionysiou K
Article: RMD OPEN. 2020;6(2):e001363
How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers
Chatzidionysiou K; Delcoigne B; Frisell T; Hetland ML; Glintborg B; Dreyer L; Cordtz R; Zobbe K; Nordstrom D; Trokovic N; Aaltonen K; Provan SA; Grondal G; Gudbjornsson B; Askling J
Article: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2020;38(5):841-847
Validation of new classification criteria of rheumatoid arthritis in an international multicentre study
Li R; Sun X; Ye H; Liu J; Zhao J; Liu X; Mei Y; Zhang Z; Guo J; Bi L; Wang G; Leng X; Gu F; Sun L; Zou Q; Fang Y; Jiang Q; Chatzidionysiou K; Priya S; Janardana R; Nair A; Catrine AI; Danda D; Li ZG
Article: RMD OPEN. 2020;6(2):e001278
Association between number and type of different ACPA fine specificities with lung abnormalities in early, untreated rheumatoid arthritis
Joshua V; Hensvold AH; Reynisdottir G; Hansson M; Cornillet M; Nogueira L; Serre G; Nyren S; Karimi R; Eklund A; Skold M; Grunewald J; Chatzidionysiou K; Catrina A
Article: RMD OPEN. 2020;6(2):e001183
Strategies for the assessment of competences during rheumatology training across Europe: results of a qualitative study.
Najm A; Alunno A; Sivera F; Ramiro S; Haines C; Working Group on Training in Rheumatology across E
Article: JOURNAL OF CLINICAL MEDICINE. 2020;9(6):E1813-1813
Use of Antimalarial Agents Is Associated with Favourable Physical Functioning in Patients with Systemic Lupus Erythematosus
Gomez A; Soukka S; Johansson P; Akerstrom E; Emamikia S; Enman Y; Chatzidionysiou K; Parodis I
Article: ARTHRITIS RESEARCH & THERAPY. 2020;22(1):56
Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort
Panopoulos S; Chatzidionysiou K; Tektonidou MG; Bournia VK; Drosos AA; Liossis S-NC; Dimitroulas T; Sakkas L; Boumpas D; Voulgari PV; Daoussis D; Thomas K; Georgiopoulos G; Vosvotekas G; Sidiropoulos P; Bertsias G; Vassilopoulos D; Sfikakis PP
Article: MEDITERRANEAN JOURNAL OF RHEUMATOLOGY. 2020;31(1):1-2
Mediterranean Journal of Rheumatology March 2020 Highlights.
Chatzidionysiou K
Article: MEDITERRANEAN JOURNAL OF RHEUMATOLOGY. 2020;31(1):87-91
Development and Implementation of a Pilot Registry for Monitoring the Efficacy and Safety of Novel Therapies in Patients with Systemic Lupus Erythematosus.
Adamichou C; Flouri I; Fanouriakis A; Nikoloudaki M; Nikolopoulos D; Repa A; Boki K; Chatzidionysiou K; Garyfallos A; Boumpas D; Sidiropoulos P; Bertsias G
Article: THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE. 2020;12:1759720X20976975
Higher depression rates and similar cardiovascular comorbidity in psoriatic arthritis compared with rheumatoid arthritis and diabetes mellitus
Fragoulis GE; Evangelatos G; Tentolouris N; Fragkiadaki K; Panopoulos S; Konstantonis G; Iliopoulos A; Chatzidionysiou K; Sfikakis PP; Tektonidou MG
Article: RHEUMATOLOGY. 2019;58(12):2170-2176
Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus
Parodis I; Johansson P; Gomez A; Soukka S; Emamikia S; Chatzidionysiou K
Article: THE LANCET RHEUMATOLOGY. 2019;1(3):E163-E173
Definitions of remission in systemic lupus erythematosus: a post-hoc analysis of two randomised clinical trials
Parodis I; Emamikia S; Gomez A; Gentline C; Arkema EV; Chatzidionysiou K; van Vollenhoven RF
Article: JOURNAL OF DIABETES RESEARCH. 2019;2019:2936962-8
Protective Effect of the HIF-1A Pro582Ser Polymorphism on Severe Diabetic Retinopathy
Ekberg NR; Eliasson S; Li YW; Zheng X; Chatzidionysiou K; Falhammar H; Gu HF; Catrina S-B
Article: EXPERT OPINION ON BIOLOGICAL THERAPY. 2019;19(2):157-168
Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies
Parodis I; Emamikia S; Gomez A; Gunnarsson I; van Vollenhoven RF; Chatzidionysiou K
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2019;48(1):17-23
Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration
Chatzidionysiou K; Lukina G; Gabay C; Hetland ML; Hauge EM; Pavelka K; Nordstrom D; Canhao H; Tomsic M; Rotar Z; Lie E; Kvien TK; van Vollenhoven RF; Saevarsdottir S
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2018;47(6):465-474
Biological treatment in ankylosing spondylitis in the Nordic countries during 2010-2016: a collaboration between five biological registries
Glintborg B; Lindstrom U; Aaltonen K; Kristianslund EK; Gudbjornsson B; Chatzidionysiou K; Askling J; Nordstrom D; Hetland ML; Di Giuseppe D; Dreyer L; Kristensen LE; Jorgensen TS; Eklund K; Grondal G; Ernestam S; Joensuu J; Tormanen MRK; Skydsgaard H; Hagfors J; Kvien TK; Lie E; Fagerli K; Geirsson AJ; Jonsson H; Provan SA; Krogh NS; Jacobsson LTH
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2018;47(2):131-140
Relationship between glucocorticoid dose and adverse events in systemic lupus erythematosus: data from a randomized clinical trial
Emamikia S; Gentline C; Chatzidionysiou K; Arnaud L; van Vollenhoven R
Article: LUPUS SCIENCE AND MEDICINE. 2018;5(1):e000287
Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort
Giannakou I; Chatzidionysiou K; Magder LS; Gyori N; van Vollenhoven R; Petri MA
Article: JOURNAL OF RHEUMATOLOGY. 2017;44(2):162-169
Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration
Chatzidionysiou K; Lie E; Lukina G; Hetland ML; Hauge E-M; Pavelka K; Gabay C; Scherer A; Nordstrom D; Canhao H; Santos MJ; Tomsic M; Rotar Z; Victoria Hernandez M; Gomez-Reino J; Ancuta I; Kvien TK; van Vollenhoven R
Journal article: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(1):314
Differences and similarities in rheumatology speciality training programmes across European countries (vol 74, pg 1183, 2015)
Sivera F; Ramiro S; Cikes N
Article: LUPUS SCIENCE AND MEDICINE. 2017;4(1):e000192
Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort.
Györi N; Giannakou I; Chatzidionysiou K; Magder L; van Vollenhoven RF; Petri M
Article: ARTHRITIS RESEARCH & THERAPY. 2016;18(1):213
Rheumatology training experience across Europe: analysis of core competences
Sivera F; Ramiro S; Cikes N; Cutolo M; Dougados M; Gossec L; Kvien TK; Lundberg IE; Mandl P; Moorthy A; Panchal S; da Silva JAP; Bijlsma JW
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2016;45(sup128):64-75
Optimizing biological treatments for rheumatoid arthritis
Chatzidionysiou K
Article: ANNALS OF THE RHEUMATIC DISEASES. 2016;75(7):1336-1342
Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study
Gabay C; Riek M; Hetland ML; Hauge E-M; Pavelka K; Tomsic M; Canhao H; Chatzidionysiou K; Lukina G; Nordstrom DC; Lie E; Ancuta I; Victoria Hernandez M; van Riel PLMC; van Vollenhoven R; Kvien TK
Article: ARTHRITIS RESEARCH & THERAPY. 2016;18:50
Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Ancuta I; Pavelka K; Nordstrom DC; Gabay C; Canhao H; Tomsic M; van Riel PLCM; Gomez-Reino J; Kvien TK; van Vollenhoven RF
Article: RHEUMATOLOGY. 2016;55(2):230-236
Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis
Walker UA; Jaeger VK; Chatzidionysiou K; Hetland ML; Hauge E-M; Pavelka K; Nordstrom DC; Canhao H; Tomsic M; van Vollenhoven R; Gabay C
Article: RMD OPEN. 2016;2(1):e000133
A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission.
Chatzidionysiou K; Turesson C; Teleman A; Knight A; Lindqvist E; Larsson P; Cöster L; Forslind K; van Vollenhoven R; Heimbürger M
Article: RMD OPEN. 2016;2(2):e000323
Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials.
Emamikia S; Arkema EV; Györi N; Detert J; Chatzidionysiou K; Dougados M; Burmester GR; van Vollenhoven R
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2015;44(6):431-437
Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register
Chatzidionysiou K; Kristensen L-E; Eriksson J; Askling J; van Vollenhoven R
Article: ANNALS OF THE RHEUMATIC DISEASES. 2015;74(6):1183-1187
Differences and similarities in rheumatology specialty training programmes across European countries
Sivera F; Ramiro S; Cikes N; Dougados M; Gossec L; Kvien TK; Lundberg IE; Mandl P; Moorthy A; Panchal S; da Silva JAP; Bijlsma JW
Article: ANNALS OF THE RHEUMATIC DISEASES. 2015;74(5):890-896
Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register
Chatzidionysiou K; Askling J; Eriksson J; Kristensen LE; van Vollenhoven R
Journal article: DIABETES RESEARCH AND CLINICAL PRACTICE. 2013;102(3):233-241
Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for end-stage renal disease/mortality in type 2 diabetes.
Campbell HM; Khan N; Raisch DW; Borrego ME; Sather MR; Murata GH
Journal article: КЛИНИЧЕСКАЯ ПРАКТИКА. 2013;10(3):233-236
Latest developments in the treatment of rheumatoid arthritis: is there new hope for patients?
Chatzidionysiou K; van Vollenhoven R
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2013;42(3):190-195
Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort
Chatzidionysiou K; van Vollenhoven RF
Article: THE LANCET. 2012;379(9827):1712-1720
Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial
van Vollenhoven RF; Geborek P; Forslind K; Albertsson K; Ernestam S; Petersson IF; Chatzidionysiou K; Bratt J
Article: ANNALS OF THE RHEUMATIC DISEASES. 2012;71(3):374-377
Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; van Riel PLCM; Nordstrom DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF; Gabay C
Article: BMJ OPEN. 2012;2(5):e001524
Influence of FCGR3A genotype on the therapeutic response to rituximab in rheumatoid arthritis: an observational cohort study
Kastbom A; Coster L; Arlestig L; Chatzidionysiou A; van Vollenhoven RF; Padyukov L; Rantapaa-Dahlqvist S; Saevarsdottir S
Article: ANNALS OF THE RHEUMATIC DISEASES. 2011;70(10):1822-1825
Delays in assessment of patients with rheumatoid arthritis: variations across Europe
Raza K; Stack R; Kumar K; Filer A; Detert J; Bastian H; Burmester GR; Sidiropoulos P; Kteniadaki E; Repa A; Saxne T; Turesson C; Mann H; Vencovsky J; Catrina A; Chatzidionysiou A; Hensvold A; Rantapaa-Dahlqvist S; Binder A; Machold K; Kwiakowska B; Ciurea A; Tamborrini G; Kyburz D; Buckley CD
Article: ANNALS OF THE RHEUMATIC DISEASES. 2011;70(9):1575-1580
Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Gabay C; van Riel PLCM; Nordstrom DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF
Article: ANNALS OF THE RHEUMATIC DISEASES. 2011;70(3):469-475
Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial
Saevarsdottir S; Wallin H; Seddighzadeh M; Ernestam SA; Geborek P; Petersson IF; Bratt J; van Vollenhoven RF
Article: THE LANCET. 2009;374(9688):459-466
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial
van Vollenhoven RF; Ernestam S; Geborek P; Petersson IF; Coster L; Waltbrand E; Zickert A; Theander J; Thorner A; Hellstrom H; Teleman A; Dackhammar C; Akre F; Forslind K; Ljung L; Oding R; Chatzidionysiou A; Wornert M; Bratt J
Visa fler

Alla övriga publikationer

Conference publication: ANNALS OF ONCOLOGY. 2023;34:s688-s689
Association of immune-related adverse events (irAE) requiring glucocorticoids (GCs) with outcome and biomarkers in advanced cutaneous malignant melanoma (CMM) treated with immune checkpoint inhibitors (ICI)
Svedman FC; Liapi M; Chatzidionysiou A; Mansson-Broberg A; Brage SE
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:856
SYSTEMATIC LITERATURE REVIEW INFORMING THE EULAR POINTS TO CONSIDER TASK FORCE ON THE INITIATION OF TARGETED THERAPIES IN PATIENTS WITH INFLAMMATORY ARTHRITIDES AND A HISTORY OF CANCER
Sebbag E; Molina Collada J; Lauper K; Aletaha D; Askling J; Benesova K; Bertheussen H; Bitoun S; Bolek EC; Burmester GR; Canhao H; Chatzidionysiou K; Curtis J; Danlos FX; Guimaraes V; Hetland ML; Iannone F; Kostine M; Kragstrup TW; Kvien TK; Regierer A; Schulze-Koops H; Silva-Fernandez L; Szekanecz Z; Buch MH; Finckh A; Gottenberg JE
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:863
SERONEGATIVE RHEUMATOID ARTHRITIS (RA) - IS IT REALLY RA?
Wettersand EB; Chatzidionysiou K
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:1164.1-111165
AN UNUSUAL INITIAL PRESENTATION OF VEXAS SYNDROME
Galindo-Feria AS; Chatzidionysiou K
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:2053-2054
RISK FACTORS FOR DEVELOPING RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS AFTER IMMUNOTHERAPY WITH IMMUNE CHECKPOINT INHIBITORS
Liapi M; Chatzidionysiou K
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:533
THE IMPACT OF IMMUNOMODULATING TREATMENT ON THE SEROLOGICAL IMMUNOGENICITY FOLLOWING THREE DOSES OF COVID-19 VACCINE AND PERSISTENCE OF IMMUNOGENICITY OF TWO VACCINE DOSES IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES - A SWEDISH STUDY (COVID19-REUMA)
Frodlund M; Nived P; Chatzidionysiou K; Sodergren A; Klingberg E; Hansson M; Pin E; Klareskog L; Kapetanovic MC
Review: RMD OPEN. 2023;9(1):e002898
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study
van der Togt CJT; van den Bemt B; Aletaha D; Alten R; Chatzidionysiou K; Galloway J; Isaac J; Mulleman D; Verschueren P; Vulto AG; Welsing PMJ; Verhoef L; den Broeder AA
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:29
EULAR POINTS TO CONSIDER ON THE INITIATION OF TARGETED THERAPIES IN PATIENTS WITH INFLAMMATORY ARTHRITIDES AND A HISTORY OF CANCER
Sebbag E; Lauper K; Collada JM; Aletaha D; Askling J; Benesova K; Bertheussen H; Bitoun S; Bolek EC; Burmester GR; Canhao H; Chatzidionysiou K; Curtis J; Danlos FX; Guimaraes V; Hetland ML; Iannone F; Kostine M; Kragstrup TW; Kvien TK; Regierer A; Schulze-Koops H; Silva-Fernandez L; Szekanecz Z; Buch MH; Finckh A; Gottenberg JE
Review: ANNALS OF THE RHEUMATIC DISEASES. 2023;82(1):3-18
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
Smolen JS; Landewe RBM; Bergstra SA; Kerschbaumer A; Sepriano A; Aletaha D; Caporali R; Edwards CJ; Hyrich KL; Pope JE; de Souza S; Stamm TA; Takeuchi T; Verschueren P; Winthrop KL; Balsa A; Bathon JM; Buch MH; Burmester GR; Buttgereit F; Cardiel MH; Chatzidionysiou K; Codreanu C; Cutolo M; den Broeder AA; El Aoufy K; Finckh A; Fonseca JE; Gottenberg J-E; Haavardsholm EA; Iagnocco A; Lauper K; Li Z; McInnes IB; Mysler EF; Nash P; Poor G; Ristic GG; Rivellese F; Rubbert-Roth A; Schulze-Koops H; Stoilov N; Strangfeld A; van der Helm-van Mil A; van Duuren E; Vliet Vlieland TPM; Westhovens R; van der Heijde D
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2022;81(8):e140
Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou et al.
Bettiol A; Pregnolato F; Sciascia S; Emmi G; Prisco D; Meroni PL
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2022;81(8):e141
Response to: 'Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou et al' by Bettiol et al
Chatzidionysiou K; Samoli E; Sfikakis PP; Tektonidou MG
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2022;81:1017
TREATMENT OF IMMUNE CHECKPOINT INHIBITOR-INDUCED INFLAMMATORY ARTHRITIS AND POLYMYALGIA RHEUMATICA
Liapi M; Chatzidionysiou K
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2022;81:588
RECOMMENDATIONS FOR COST-EFFECTIVE USE OF BIOLOGICAL AND TARGETED SYNTHETIC DMARDS IN INFLAMMATORY ARTHRITIS: RESULTS FROM AN INTERNATIONAL DELPHI STUDY
Van der Togt C; Van den Bemt B; Aletaha D; Alten R; Chatzidionysiou K; Galloway J; Isaacs J; Mulleman D; Verschueren P; Vulto A; Welsing P; Verhoef LM; Den Broeder A
Review: BIOMEDICINE & PHARMACOTHERAPY. 2022;148:112687
Comparison of immune checkpoint inhibitor-induced arthritis and reactive arthritis to inform therapeutic strategy
Jensen AK; Chatzidionysiou K; Torp CK; Sorensen AS; Tenstad HB; Schafer VS; Kostine M; Jacobsen S; Leipe J; Kragstrup TW
Editorial comment: FRONTIERS IN MEDICINE. 2022;9:1020859
Editorial: Advance in B-cell therapies for the treatment of rheumatic and musculoskeletal diseases.
Md Yusof MY; Alivernini S; Chatzidionysiou K
Review: LAKARTIDNINGEN. 2021;118:21114
[Overview of immune-related side effects from immune checkpoint inhibitors. Part 2: Endocrine, rheumatologic and skin toxicity].
Helgadottir H; Falkenius J; Eriksson H; Girnita A; Sahlberg L; Bensing S; Chatzidionysiou K; Masucci G; Ullenhag G
Corrigendum: JOURNAL OF DIABETES RESEARCH. 2021;2021:9827150-1
Protective Effect of the HIF-1A Pro582Ser Polymorphism on Severe Diabetic Retinopathy (vol 2019, 2936962, 2019)
Ekberg NR; Eliasson S; Li YW; Zheng X; Chatzidionysiou K; Falhammar H; Gu HF; Catrina S-B
Review: CLINICAL RHEUMATOLOGY. 2021;40(5):1687-1695
Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors-is it time for a paradigm shift?
Chatzidionysiou K; Liapi M; Tsakonas G; Gunnarsson I; Catrina A
Review: MEDITERRANEAN JOURNAL OF RHEUMATOLOGY. 2020;31(Suppl 1):120-128
Beyond Methotrexate and Biologics in RA - Efficacy of JAK Inhibitors and their Place in the Current Treatment Armamentarium.
Chatzidionysiou K
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2020;79:762-763
SIMILAR CARDIOVASCULAR COMORBIDITY AND HIGHER DEPRESSION RATES IN PSORIATIC ARTHRITIS COMPARED TO AGE- AND SEX-MATCHED RHEUMATOID ARTHRITIS AND DIABETES MELLITUS PATIENTS
Fragoulis GE; Evangelatos G; Tentolouris N; Fragkiadaki K; Panopoulos S; Konstantonis G; Iliopoulos A; Chatzidionysiou K; Sfikakis P; Tektonidou M
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2020;79:1004.1-1004
COMPARATIVE RISK OF CANCER ASSOCIATED WITH FIRST-LINE DMARDS USE IN RHEUMATOID ARTHRITIS: REAL WORLD EVIDENCE FROM THE OHDSI NETWORK
Duarte-Salles T; Recalde M; Weaver J; Burn E; Marinier K; Diaz Y; Illingens B; Vizcaya D; Chatzidionysiou K; Ryan P; Prieto-Alhambra D
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2020;79:134.2-134
DEVELOPMENT AND VALIDATION OF PATIENT-LEVEL PREDICTION MODELS FOR ADVERSE HEALTH OUTCOMES AMONGST ADULT RA PATIENTS INITIATING FIRST-LINE TREATMENT OF METHOTREXATE MONOTHERAPY: A MULTINATIONAL REAL-WORLD COHORT ANALYSIS INCLUDING 164,735 SUBJECTS
Yang C; Williams R; Swerdel J; Jani M; Duarte-Salles T; Chatzidionysiou K; Prieto-Alhambra D; Ryan P; Rijnbeek P
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2020;79:331.1-331
FIRST LINE TREATMENT WITH CONVENTIONAL SYNTHETIC DISEASE MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS: A MULTINATIONAL POPULATION-BASED COHORT FROM 14 REAL WORLD HEALTHCARE DATABASES AND 9 COUNTRIES - REALITY VERSUS GUIDELINES
Sena AG; Granados D; Hughes N; Fakhouri W; Hottgenroth A; Kolde R; Reisberg S; Torre CO; Duarte-Salles T; Diaz Y; Golib-Dzib JF; Brouwer ES; Burn E; Lane J; Vizcaya D; Wirta SB; De Wilde M; Verhamme K; Rijnbeek P; Theander E; Chatzidionysiou K; Prieto-Alhambra D; Ryan P
Letter: LUPUS SCIENCE AND MEDICINE. 2020;7(1):e000415
Could severe COVID-19 be considered a complementopathy?
Chatzidionysiou K; Svenungsson E; Faustini F
Review: CLINICAL RHEUMATOLOGY. 2020;39(3):957-961
Lung cancer in rheumatoid arthritis. Is there a need for better risk assessment and screening?
Fragoulis GE; Chatzidionysiou K
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2020;79(2):304-307
Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus
Chatzidionysiou K; Samoli E; Sfikakis PP; Tektonidou MG
Review: BEST PRACTICE AND RESEARCH: CLINICAL RHEUMATOLOGY. 2019;33(5):101476
Established rheumatoid arthritis - Redefining the concept
Chatzidionysiou K; Fragoulis GE
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2019;78(7):1006-1007
Established organ damage reduces belimumab efficacy in systemic lupus erythematosus
Parodis I; Gomez A; Emamikia S; Chatzidionysiou K
Review: MEDITERRANEAN JOURNAL OF RHEUMATOLOGY. 2019;30(2):103-109
Rheumatic disease and artistic creativity.
Chatzidionysiou K
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2019;78:761
PREDICTORS OF LOW DISEASE ACTIVITY AND CLINICAL REMISSION FOLLOWING BELIMUMAB TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS
Parodis I; Johansson P; Gomez A; Soukka S; Emamikia S; Chatzidionysiou K
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2019;78:703-704
EFFECTIVENESS OF TNF INHIBITORS VS. NON-TNF INHIBITORS (ABATACEPT, TOCILIZUMAB AND RITUXIMAB) AFTER FAILURE OF NON-TNFI BIOLOGIC DMARD IN RHEUMATOID ARTHRITIS - COLLABORATION BETWEEN FIVE NATIONAL REGISTERS
Chatzidionysiou K; Hetland ML; Frisell T; Di Giuseppe D; Hellgren K; Glintborg B; Nordstrom D; Aaltonen K; Trokovic N; Kristianslund E; Kvien TK; Provan SA; Gudbjornsson B; Grondal G; Dreyer L; Kristensen LE; Jorgensen TS; Jacobsson LTH; Askling J
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2019;78:781-782
ANTIMALARIAL AGENTS IMPROVE PHYSICAL FUNCTIONING IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Parodis I; Soukka S; Gomez A; Enman Y; Johansson P; Emamikia S; Chatzidionysiou K
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2019;78:1800.1-1800
ANTIPROLIFERATIVE AND VASOACTIVE TREATMENT MODALITIES IN 457 CONSECUTIVE PATIENTS WITH SYSTEMIC SCLEROSIS FROM ACADEMIC CENTERS IN GREECE
Panopoulos S; Tektonidou M; Chatzidionysiou K; Drosos A; Liossis S-N; Dimitroulas T; Sakkas L; Boumpas D; Sidiropoulos P; Bertsias G; Voulgari PV; Daoussis D; Thomas K; Georgiopoulos G; Vosvotekas G; Vassilopoulos D; Sfikakis P
Corrigendum: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2019;48(3):258
Comparing patient-reported outcomes entered at home versus at hospital, and testing touch screens for initial recruitment to scientific trials in arthritis patients (vol 48, pg 178, 2019)
Glintborg B; Lindstrom U; Aaltonen K; Kristianslund E; Gudbjornsson B; Chatzidionysiou K; Askling J; Nordstrom D; Hetland M; Di Giuseppe D; Dreyer L; Kristensen LE; Jorgensen TS; Eklund K; Grondal G; Ernestam S; Joensuu J; Tormanen MEK; Skydsgaard H; Hagfors J; Kvien TK; Lie E; Fagerli K; Geirsson AJ; Jonsson H; Provan SA; Krogh NS; Jacobsson LTH
Review: RMD OPEN. 2019;5(2):e000993
Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift
Chatzidionysiou K; Sfikakis PP
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2018;77:891
SIGNIFICANT DECREASE OF T-CELLS BUT NOT MACROPHAGES IN THE SYNOVIUM OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AFTER TREATMENT WITH TOCILIZUMAB
Chatzidionysiou K; Engstrom M; af Klint E; Hensvold A; Catrina AI
Review: ANNALS OF THE RHEUMATIC DISEASES. 2018;77(4):476-479
2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis
Radner H; Chatzidionysiou K; Nikiphorou E; Gossec L; Hyrich KL; Zabalan C; van Eijk-Hustings Y; Williamson PR; Balanescu A; Burmester GR; Carmona L; Dougados M; Finckh A; Haugeberg G; Hetland ML; Oliver S; Porter D; Raza K; Ryan P; Santos MJ; van der Helm-van Mil A; van Riel P; von Krause G; Zavada J; Dixon WG; Askling J
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2018;77:A39-A40
SIGNIFICANT DECREASE OF T-CELLS BUT NOT MACROPHAGES IN THE SYNOVIUM OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AFTER TREATMENT WITH TOCILIZUMAB
Chatzidionysiou K; Engstrom M; Af Klint E; Hensvold A; Catrina AI
Corrigendum: RMD OPEN. 2018;4(1)
Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example (vol 4, e000655, 2018)
Chatzidionysiou K; Hetland ML; Frisell T
Corrigendum: RMD OPEN. 2018;4(1):rmdopen-2018-000655corr1
Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example (vol 4, e000655, 2018)
Chatzidionysiou K; Hetland ML; Frisell T
Review: RMD OPEN. 2018;4(1):e000655
Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example
Chatzidionysiou K; Hetland ML; Frisell T; Di Giuseppe D; Hellgren K; Glintborg B; Nordstrom D; Aaltonen K; Tormanen MRK; Kristianslund EK; Kvien TK; Provan SA; Guobjornsson B; Dreyer L; Kristensen LE; Jorgensen TS; Jacobsson L; Askling J
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2017;76:69-70
PREDICTORS OF PERSISTENT DISEASE ACTIVITY AND PERSISTENT LONG QUIESCENCE IN SYSTEMIC LUPUS ERYTHEMATOSUS - RESULTS FROM THE HOPKINS LUPUS COHORT
Giannakou I; Chatzidionysiou K; Magder L; van Vollenhoven R; Petri M
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2017;76:1027
HOW DO WE USE BIOLOGICS IN PATIENTS WITH A HISTORY OF MALIGNANCY? AN ASSESSMENT OF TREATMENT PATTERNS USING SCANDINAVIAN REGISTERS
Chatzidionysiou K; Aaltonen K; Nordstrom D; Gudbjornsson B; Grondal G; Geirsson AJ; Steingrimsdottir L; Frisell T; Askling J
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2017;76:567
DOES SEROPOSITIVITY INFLUENCE DIFFERENTIALLY DRUG DISCONTINUATION OF BIOLOGIC ANTIRHEUMATIC AGENTS WITH NON-ANTI-TNF MODE OF ACTION?
Finckh A; Courvoisier D; Gottenberg J-E; Marlette X; Morel J; Bergstra SA; Hernandez V; Codreanu C; Kviens TK; Santos MJ; Pavelka K; Hetland M; Chatzidionysiou K; Askling J; Turesson C; Gabay C; Van Vollenhoven R
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2017;76:517-518
DETERMINING MINIMUM CLINICALLY IMPORTANT CHANGE IN MULTI BIOMARKER DISEASE ACTIVITY SCORE ASSOCIATED WITH CLINICAL IMPROVEMENT IN METHOTREXATE NAIVE PATIENTS WITH EARLY RHEUMATOID ARTHRITIS
Chatzidionysiou K; Hensvold AH; Saevarsdottir S; Bolce RJ; Chernoff D; Hwang CC; Wang X; Catrina AI
Review: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(6):960-977
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Smolen JS; Landewe R; Bijlsma J; Burmester G; Chatzidionysiou K; Dougados M; Nam J; Ramiro S; Voshaar M; van Vollenhoven R; Aletaha D; Aringer M; Boers M; Buckley CD; Buttgereit F; Bykerk V; Cardiel M; Combe B; Cutolo M; van Eijk-Hustings Y; Emery P; Finckh A; Gabay C; Gomez-Reino J; Gossec L; Gottenberg J-E; Hazes JMW; Huizinga T; Jani M; Karateev D; Kouloumas M; Kvien T; Li Z; Mariette X; McInnes I; Mysler E; Nash P; Pavelka K; Poor G; Richez C; van Riel P; Rubbert-Roth A; Saag K; da Silva J; Stamm T; Takeuchi T; Westhovens R; de Wit M; van der Heijde D
Review: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(6):1102-1107
Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of The EULAR recommendations for the management of rheumatoid arthritis
Chatzidionysiou K; Emamikia S; Nam J; Ramiro S; Smolen J; van der Heijde D; Dougados M; Bijlsma J; Burmester G; Scholte M; van Vollenhoven R; Landewe R
Review: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(6):1101-1136
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis
Ramiro S; Sepriano A; Chatzidionysiou K; Nam JL; Smolen JS; van der Heijde D; Dougados M; van Vollenhoven R; Bijlsma JW; Burmester GR; Scholte-Voshaar M; Falzon L; Landewe RBM
Review: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(6):1113-1136
Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis
Nam JL; Takase-Minegishi K; Ramiro S; Chatzidionysiou K; Smolen JS; van der Heijde D; Bijlsma JW; Burmester GR; Dougados M; Scholte-Voshaar M; van Vollenhoven R; Landewe R
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2017;76:686
PRESCRIPTION PATTERNS OF TUMOUR NECROSIS FACTOR INHIBITOR AND USTEKINUMAB IN PSORIATIC ARTHRITIS: A NORDIC POPULATION-BASED COHORT STUDY
Jorgensen TS; Dreyer L; Gudbjornsson B; Hetland ML; Glintborg B; Askling J; Chatzidionysiou K; Di Giuseppe D; Jacobsson L; Wallman JK; Kristianslund EK; Olsen IC; Fagerli K; Lie E; Nordstrom D; Aaltonen K; Joensuu J; Love TJ; Geirsson AJ; Kristensen LE
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2017;76:341.2-342
PRESCRIPTION PATTERNS OF BIOLOGICAL DISEASE MODIFYING DRUGS AND BIOSIMILARS IN ANKYLOSING SPONDYLITIS - A COLLABORATION BETWEEN BIOLOGICAL REGISTERS IN THE FIVE NORDIC COUNTRIES
Glintborg B; Chatzidionysiou K; Askling J; Aaltonen K; Kristianslund E; Gudbjornsson B; Nordstrom D; Hetland ML; Dreyer L; Kristensen LE; Jorgensen TS; Eklund K; Grondal G; Ernestam S; Joensuu J; Kvien T; Lie E; Fagerli K; Geirsson AJ; Jonsson H; Jacobsson L
Conference publication: SWISS MEDICAL WEEKLY. 2017;147:3S
Does seropositivity influence differentially drug discontinuation of biologic antirheumatic agents with non-anti-TNF mode of action?
Finckh A; Courvoisier DS; Gottenberg J-E; Mariette X; Morel J; Bergstra SA; Hernandez V; Codreanu C; Kvien TK; Santos MJ; Pavelka K; Hetland M; Chatzidionysiou K; Askling J; Turesson C; Gabay C; Van Vollenhoven R
Review: ARTHRITIS RESEARCH & THERAPY. 2016;18(1):251
Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature
Nikiphorou E; Radner H; Chatzidionysiou K; Desthieux C; Zabalan C; van Eijk-Hustings Y; Dixon WG; Hyrich KL; Askling J; Gossec L
Corrigendum: ARTHRITIS RESEARCH & THERAPY. 2016;18(1):144
Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration (vol 18, 50, 2016)
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Ancuta I; Pavelka K; Nordstrom DC; Gabay C; Canhao H; Tomsic M; van Riel PLCM; Gomez-Reino J; Kvien TK; van Vollenhoven RF
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2016;75:166
THE EULAR TASK FORCE FOR STANDARDISING MINIMUM DATA COLLECTION IN RHEUMATOID ARTHRITIS OBSERVATIONAL RESEARCH: RESULTS OF A HIERARCHICAL LITERATURE REVIEW
Chatzidionysiou K; Nikiphorou E; Gossec L; Hyrich K; Filip C; van Eijk-Hustings Y; Williamson P; Dixon W; Askling J; Radner H
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2016;75:477-478
ASSOCIATION BETWEEN NUMBER AND TYPE OF DIFFERENT ACPA FINE SPECIFICITIES AND PARENCHYMAL LUNG CHANGES IN HIGH RESOLUTION COMPUTED TOMOGRAPHY IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS
Joshua V; Chatzidionysiou K; Reynisdottir G; Hensvold AH; Hansson M; Nogueira L; Eklund A; Serre G; Grunewald J; Catrina AI
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2016;75:299-300
RELATIONSHIP BETWEEN CORTICOSTEROIDS AND UNFAVORABLE MEDICAL EFFECTS. A STUDY UNDER THE SHARE SYSTEM BASED ON THE CLINICAL TRIAL BELIMUMAB IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (BLISS-76)
Emamikia S; Gentline C; Backheden M; Chatzidionysiou K; Arnaud L; van Vollenhoven RF
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2016;75:477
RISK FOR LUNG CANCER IN RA AND DIFFERENT RA PHENOTYPES: RESULTS FROM A POPULATION-BASED CASE-CONTROL STUDY
Chatzidionysiou K; Reynisdottir G; Joshua V; Frisell T; Askling J; Catrina A
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2016;75:499
INDUCTION-MAINTENANCE IN EARLY RA: A META-ANALYSIS OF TRIALS USING MTX PLUS TNF-INHIBITOR AS INDUCTION THERAPY
Emamikia S; Arkema EV; Detert J; Chatzidionysiou K; Dougados M; Burmester GR; van Vollenhoven RF
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2016;75:406.3-407
TOWARDS DEVELOPMENT OF A MINIMUM CORE DATASET AND STANDARDS OF DATA COLLECTION FOR OBSERVATIONAL RHEUMATOID ARTHRITIS RESEARCH A EULAR INITIATIVE
Radner H; Nikiphorou E; Chatzidionysiou K; Gossec L; Hyrich K; Filip C; van Eijk-Hustings Y; Williamson P; Dixon W; Askling J
Corrigendum: CURRENT OPINION IN RHEUMATOLOGY. 2016;28(2):1
The lung in rheumatoid arthritis, cause or consequence? Erratum.
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2016;75:A79
RISK FOR LUNG CANCER IN RA AND DIFFERENT RA PHENOTYPES: RESULTS FROM A POPULATION-BASED CASE-CONTROL STUDY
Chatzidionysiou K; Reynisdottir G; Joshua V; Frisell T; Askling J; Catrina AI
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2015;74:484-485
SMOKING AND RESPONSE TO RITUXIMAB IN ANTI-CCP POSITIVE AND NEGATIVE RHEUMATOID ARTHRITIS - RESULTS FROM AN INTERNATIONAL EUROPEAN COLLABORATION
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Hauge E; Pavelka K; Gabay C; Nordstrom D; Canhao H; Tomsic M; van Riel P; Gomez-Reino J; Ancuta I; Kvien T; van Vollenhoven R; Saevarsdottir S
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2015;74:798-799
DISEASE ACTIVITY PATTERNS OVER TIME IN PATIENTS WITH SLE - A RETROSPECTIVE DESCRIPTIVE ANALYSIS OF THE HOPKINS LUPUS COHORT
Gyori N; Chatzidionysiou A; Magder L; van Vollenhoven R; Petri M
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2015;74:492
RITUXIMAB DONE! WHAT'S NEXT IN RHEUMATOID ARTHRITIS? A EUROPEAN OBSERVATIONAL LONGITUDINAL STUDY ASSESSING THE EFFECTIVENESS OF BIOLOGICS AFTER RITUXIMAB TREATMENT IN RHEUMATOID ARTHRITIS
Walker UA; Jaeger VK; Chatzidionysiou K; Hetland ML; Hauge E-M; Pavelka K; Nordstrom DC; Canhao H; Tomsic M; van Vollenhoven R; Gabay C
Conference publication: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2015;33(3):S65-S66
Disease activity patterns over time in patients with SLE - A retrospective descriptive analysis of the Hopkins Lupus Cohort
Gyori N; Chatzidionysiou A; Magder L; van Vollenhoven R; Petri M
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2014;73:601-602
RETENTION OF TOCILIZUMAB THERAPY: A COMPARISON BETWEEN TOCILIZUMAB IN MONOTHERAPY AND IN COMBINATION WITH DMARDS BASED ON THE TOCERRA COLLABORATION
Gabay C; Riek M; Hetland M; Hauge EM; Pavelka K; Tomsic M; Canhao H; Chatzidionysiou K; van Vollenhoven R; Lukina G; Nordstrom D; Lie E; Ancuta I; Loza Santamaria E; van Riel P; Kvien T
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2014;73:674
EFFECTIVENESS OF REPEATED COURSES OF RITUXIMAB IN RA - RESULTS FROM THE CERERRA COLLABORATION
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Pavelka K; Gabay C; Nordstrom DC; Canhao H; Tomsic M; van Riel PL; Gomez-Reino J; Ancuta I; Kvien TK; van Vollenhoven RF
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2014;73:505-506
FIXED VERSUS ON-FLARE RETREATMENT WITH RITUXIMAB IN RA - RESULTS FROM THE CERERRA COLLABORATION
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Pavelka K; Gabay C; Nordstrom DC; Canhao H; Tomsic M; van Riel PL; Gomez-Reino J; Ancuta I; Kvien TK; van Vollenhoven RF
Thesis / dissertation: 2014
Biological therapy in rheumatoid arthritis : epidemiological studies
Chatzidionysiou, Katerina
Editorial comment: NATURE REVIEWS. RHEUMATOLOGY. 2013;9(9):510-512
RHEUMATOID ARTHRITIS Triple therapy or etanercept after methotrexate failure in RA?
van Vollenhoven RF; Chatzidionysiou K
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2013;71:517-518
TREATMENT WITH CERTOLIZUMAB PEGOL IN RA - DATA FROM THE NATIONAL REGISTRY ARTIS (ANTIRHEUMATIC THERAPIES IN SWEDEN)
Chatzidionysiou K; van Vollenhoven R
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2013;71:182
SEROPOSITIVITY AND RESPONSE TO RTX: DATA FROM THE CERERRA COLLABORATION
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland M; Tarp U; Ancuta I; Pavelka K; Nordstrom D; Gabay C; Canhao H; Tomsic M; van Riel P; Gomez-Reino J; Kvien T; van Vollenhoven R
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2013;71:62
EFFICACY OF DIFFERENT DOSES OF RITUXIMAB FOR THE TREATMENT OF RA: DATA FROM THE CERERRA COLLABORATION
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland M; Tarp U; Ancuta I; Pavelka K; Nordstrom D; Gabay C; Canhao H; Tomsic M; van Riel P; Gomez-Reino J; Kvien T; van Vollenhoven R
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2012;71:A14-U75
EFFICACY OF TNF SWITCH AFTER FAILURE OF ONE TNF INHIBITOR - RESULTS FROM A NATION-WIDE OBSERVATIONAL STUDY
Chatzidionysiou K; Eriksson J; Askling J; van Vollenhoven RF
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2012;71:a13-A14
EFFICACY OF DIFFERENT DOSES OF RITUXIMAB FOR THE TREATMENT OF RA: DATA FROM THE CERERRA COLLABORATION
Chatzidionysiou K; Lie E; Nasonov EL; Lukina G; Hetland ML; Tarp U; Ancuta I; Pavelka K; Nordstrom DC; Gabay C; Canhao H; Tomsic M; van Riel PLC; Gomez-Reino JJ; Kvien TK; van Vollenhoven RF
Review: JOURNAL OF INTERNAL MEDICINE. 2011;269(6):614-625
When to initiate and discontinue biologic treatments for rheumatoid arthritis?
Chatzidionysiou K; van Vollenhoven RF
Visa fler

Forskningsbidrag

Optimal Treatment of Early Rheumatoid Arthritis: The NORD-STAR randomized trial embedded in the Swedish Rheumatology Quality Register SRQ: Combining Pragmatic Trials and National Registers...
Swedish Research Council
1 January 2015 - 31 December 2017

Anställningar

Anknuten till Forskning, Medicin, Solna, Karolinska Institutet, 2023-2026

Examina och utbildning

Docent, reumatologi, Karolinska Institutet, 2020
Medicine Doktorsexamen, Institutionen för medicin, Solna, Karolinska Institutet, 2014

Handledare

Marie-Louise Karlsson, The impact of lifestyle changes, and treatment adherence in Early Rheumatoid Arthritis, 2023

Artiklar

Alla övriga publikationer

Forskningsbidrag

Anställningar

Examina och utbildning

Handledare

Nyheter från KI

Kalenderhändelser från KI